{{Rsnum
|rsid=474320
|Chromosome=11
|Orientation=plus
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene=LOC101054525
|position=101143818
|Gene_s=LOC101054525
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 7.7 | 21.5 | 70.8
| HCB | 0.0 | 2.2 | 97.8
| JPT | 0.0 | 0.0 | 100.0
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 2.2 | 97.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}Part of a haplotype [[Gs286]], standalone effect for [[endometrial cancer]] is ambiguous. Tightly linked with [[PROGINS]] [[allele]] [[rs1042838]].

No statistically significant interaction with 17-alpha-hydroxyprogesterone caproate for reducing recurrent preterm birth detected. {{PMID|21600550|OA=1
}}

{{PMID Auto GWAS
|PMID=20547493
|Trait=Endometrial cancer
|Title=Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach.
|RiskAllele=T
|Pval=0.47
|OR=1.18
|ORtxt=[0.96-1.45]
|OA=1
}}

{{PMID|22105149}} Progestogen levels, progesterone receptor gene polymorphisms, and mammographic density changes: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study

{{PMID|21600550|OA=1
}} Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate

{{PMID|15632380}} Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}